Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Cancer Sci
2012 Jul 01;1037:1189-94. doi: 10.1111/j.1349-7006.2012.02279.x.
Show Gene links
Show Anatomy links
Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
Yano S
,
Takeuchi S
,
Nakagawa T
,
Yamada T
.
???displayArticle.abstract???
Recent advances in molecular biology have led to the identification of new molecular targets, such as epidermal growth factor receptor ( EGFR ) mutations and echinoderm microtubule-associated protein-like 4 (EML4) - anaplastic lymphoma kinase (ALK) fusion gene, in lung cancer. Dramatic response has been achieved with EGFR inhibitors (gefitinib and erlotinib) and an ALK inhibitor (crizotinib) in lung cancer expressing corresponding targets. However, cancer cells acquire resistance to these drugs and cause recurrence. Known major mechanisms for resistance to molecular targeted drugs include gatekeeper mutations in the target gene and activation of bypass survival signal via receptors other than the target receptors. The latter mechanism can involve receptor gene amplification and ligand-triggered receptor activation as well. For example, hepatocyte growth factor (HGF), the ligand of a tyrosine kinase receptor Met, activates Met and the downstream PI3K/Akt pathway and triggers resistance to EGFR inhibitors in EGFR mutant lung cancer cells. Moreover, EGFR ligands activate EGFR and downstream pathways and trigger resistance to crizotinib in EML4-ALK lung cancer cells. These observations indicate that signals from oncogenic drivers (EGFR signaling in EGFR -mutant lung cancer and ALK signaling in EML4-ALK lung cancer) and ligand-triggered bypass signals (HGF-Met and EGFR ligands-EGFR, respectively) must be simultaneously blocked to avoid the resistance. This review focuses specifically on receptor activation by ligand stimulation and discusses novel therapeutic strategies that are under development for overcoming resistance to molecular targeted drugs in lung cancer.
Bergethon,
ROS1 rearrangements define a unique molecular class of lung cancers.
2012, Pubmed
Bergethon,
ROS1 rearrangements define a unique molecular class of lung cancers.
2012,
Pubmed
Choi,
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
2010,
Pubmed
,
Echinobase
Donev,
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
2011,
Pubmed
Engelman,
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
2008,
Pubmed
Engelman,
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
2007,
Pubmed
Faber,
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
2011,
Pubmed
Fukuoka,
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
2003,
Pubmed
Grotegut,
Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail.
2006,
Pubmed
Guix,
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
2008,
Pubmed
Hammerman,
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
2011,
Pubmed
Harvey,
Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas.
1996,
Pubmed
Herbst,
Lung cancer.
2008,
Pubmed
Heuckmann,
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
2011,
Pubmed
Ichimura,
Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.
1996,
Pubmed
Inamura,
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
2009,
Pubmed
,
Echinobase
Jackman,
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
2010,
Pubmed
Jin,
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.
2008,
Pubmed
Katayama,
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
2011,
Pubmed
,
Echinobase
Katayama,
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
2012,
Pubmed
Kobayashi,
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
2005,
Pubmed
Kuba,
HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
2000,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Maemondo,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
2010,
Pubmed
McCoy,
Characterization of a human colon/lung carcinoma oncogene.
1983,
Pubmed
Mitsudomi,
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
2010,
Pubmed
Nakamura,
Molecular cloning and expression of human hepatocyte growth factor.
1989,
Pubmed
Nakamura,
Hepatocyte growth factor twenty years on: Much more than a growth factor.
2011,
Pubmed
Nakamura,
Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions.
1997,
Pubmed
Ohe,
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
2007,
Pubmed
Okamoto,
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
2010,
Pubmed
Olivero,
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas.
1996,
Pubmed
Onitsuka,
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
2010,
Pubmed
Paez,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
2004,
Pubmed
Pao,
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
2010,
Pubmed
Pao,
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
2005,
Pubmed
Pirker,
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
2009,
Pubmed
Pirker,
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
2012,
Pubmed
Rong,
Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.
1994,
Pubmed
Sakamoto,
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
2011,
Pubmed
Sasaki,
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
2010,
Pubmed
Sasaki,
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
2011,
Pubmed
Schiller,
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
2002,
Pubmed
Sequist,
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
2011,
Pubmed
Sharma,
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
2010,
Pubmed
Shaw,
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
2011,
Pubmed
Siegfried,
Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
1997,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Stabile,
Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.
2006,
Pubmed
Suda,
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
2010,
Pubmed
Tokunou,
c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma.
2001,
Pubmed
Turke,
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
2010,
Pubmed
Wang,
Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
2009,
Pubmed
Wang,
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
2012,
Pubmed
Yamada,
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
2010,
Pubmed
Yamada,
Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
2012,
Pubmed
Yamada,
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
2012,
Pubmed
Yamamoto,
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
2010,
Pubmed
Yano,
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
2008,
Pubmed
Yano,
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
2011,
Pubmed
Yano,
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
2005,
Pubmed
Yasuda,
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
2012,
Pubmed